[Effects of transdermal buprenorphine in cancer patients. Results from the Cancer Pain Outcome Research (CPOR) Study Group].

Abstract

Pain still afflicts most cancer patients, mainly in the metastatic phases, and undertreatment is well documented. Transdermal delivery systems (TDS) could potentially have advantages over oral and parental routes, but evidence from comparative trials are scanty. In the framework of a wider initiative, an Outcome Research Study was carried out in Italy in 2006 to evaluate the effects of various analgesic options, particularly TDS Buprenorphine. Despite the limitations due to the observational design, these findings may be useful to clinicians to better judge the value of the drug under evaluation and to help researchers to design further comparative studies.

• Authors: Maria Teresa Greco, Silvia Deandrea, Oscar Corli, Mauro Montanari, Augusto Caraceni, Giovanni Apolone, Cancer Pain Outcome Research Study Group
• Journal: Recenti progressi in medicina (Recenti Prog Med) Vol. 99 Issue 11 Pg. 538-51 (Nov 2008) ISSN: 0034-1193 [Print] Italy
• Vernacular Title: Effetti della somministrazione di buprenorfina transdermica in pazienti oncologici. Risultati di uno studio di outcome.
• PMID: 19209537 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Analgesics, Opioid
• Buprenorphine

Topics

• Administration, Cutaneous
• Analgesics, Opioid (administration & dosage)
• Buprenorphine (administration & dosage)
• Chronic Disease
• Dose-Response Relationship, Drug
• Female
• Humans
• Italy
• Male
• Middle Aged
• Neoplasms (drug therapy)
• Outcome Assessment, Health Care (methods)
• Pain (drug therapy)
• Pain Measurement
• Palliative Care (methods)
• Prospective Studies
• Quality of Life
• Research Design
• Surveys and Questionnaires
• Treatment Outcome